US20150164817A1 - Composition comprising a benzimidazole and process for its manufacture - Google Patents
Composition comprising a benzimidazole and process for its manufacture Download PDFInfo
- Publication number
- US20150164817A1 US20150164817A1 US14/633,766 US201514633766A US2015164817A1 US 20150164817 A1 US20150164817 A1 US 20150164817A1 US 201514633766 A US201514633766 A US 201514633766A US 2015164817 A1 US2015164817 A1 US 2015164817A1
- Authority
- US
- United States
- Prior art keywords
- core
- composition
- parts
- pat
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
Definitions
- the invention relates to a novel composition comprising a benzimidazole, said composition being notably free of any binder.
- the invention also relates to a very simple process for the manufacture of the present composition.
- Benzimidazoles are known proton pump inhibitors. Representatives of this class of drugs are omeprazole, esomeprazole, pantoprazole, rabeprazole. Many formulation patents are known for this type of active pharmaceutical ingredient.
- WO-A-9712581 discloses a composition exempt of alkaline-reacting compounds comprising:
- a core containing a benzimidazole active ingredient said core being constituted of nuclei and said active ingredient mixed together and then compressed together, and said active ingredient not being in the form of an alkaline salt, and where a polymer acting as a binder is generally used in the core manufacture;
- U.S. Pat. No. 5,997,903 discloses a medicament in pellet or tablet form which contains the active compound pantoprazole, which is to be administered orally, is resistant to gastric juice and consists of a basic pellet core or tablet core, one or more inert, water-soluble intermediate layer(s) and an outer layer which is resistant to gastric juice, and which is characterized in that the core contains, in addition to pantoprazole or in addition to a pantoprazole salt, polyvinylpyrrolidone and/or hydroxypropylmethylcellulose as the binder, and if desired mannitol additionally as an inert filler.
- US2003114494 discloses a stable oral pharmaceutical which comprises a benzimidazole, comprising:
- an active ingredient layer which comprises the benzimidazole mixed with an acidic reacting compound and, where appropriate, pharmaceutically acceptable adjuvants among which binders (water-soluble polymers) which are always used in this document;
- tablette is only mentioned and is not exemplified; this document is in fact essentially towards the pellet form.
- the invention provides new benzimidazole compositions, especially the following compositions:
- composition comprising a benzimidazole active ingredient, said composition comprising:
- said core being substantially free of binder; or said core being substantially free of PVP and of HPMC.
- composition comprising a benzimidazole active ingredient, said composition comprising:
- composition comprising a benzimidazole active ingredient, said composition comprising:
- a composition comprising a benzimidazole active ingredient not being in the form of an alkaline salt, said composition being exempt of alkaline-reacting compounds, said composition comprising:
- the invention also provides a process for manufacturing the compositions of the invention, said process comprising the steps of: (i) granulating said active ingredient with said diluents, said disintegrant and said lubricant if any; (ii) compressing the product of step (i) to form a tablet core containing an active ingredient; (iii) coating said core with said intermediate layer; and (iv) coating a product from step (iii) with said enteric layer.
- the invention is designed for any benzimidazole, which is a class of compounds that is generally known.
- the expression “benzimidazole active ingredient” should be taken to mean benzimidazole derivatives that are of therapeutic value.
- the benzimidazole active ingredients as used in the instant application are notably, but not limitatively, disclosed in the following patents and patent applications: EP-A-0,005,129, EP-A-0,080,602, EP-A-0,127,763, EP-A-0,130,729, EP-A-0,134,400, EP-A-0,146,370, EP-A-0,150,586, EP-A-0,166,287, EP-A-0,173,664, EP-A-0,244,380, DE-3,415,971, GB-A-2,082,580, GB-A-2,141,429, GB-A-2163747, U.S.
- the instant invention notably applies to omeprazole, esomeprazole, pantoprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, timoprazole, aripiprazole and diapiprazole.
- alkaline salt form or derivative of the active ingredients cited above is also suitable in one embodiment.
- Derivatives such as salts (hydrates such as sesquihydrates, etc.), alkaline salts (salts formed with lithium, sodium, magnesium, potassium, calcium etc. as well as any other base), esters and the like (including pro-drugs), are also contemplated. It is also possible to use an alkaline-reacting agent together with the benzimidazole active ingredient.
- agents which may be mentioned here are the pharmacologically tolerated alkali metal, alkaline earth metal or earth metal salts of weak acids and the pharmacologically tolerated hydroxides and oxides of alkaline earth and earth metals, such as sodium carbonate, calcium carbonate, magnesium carbonate, magnesium oxide and magnesium hydroxide, Acidic reacting-agent such as those disclosed in US2003114494, notably sodium dihydrogen phosphate (NaH 2 PO 4 ), can also be used.
- alkali metal alkaline earth metal or earth metal salts of weak acids
- hydroxides and oxides of alkaline earth and earth metals such as sodium carbonate, calcium carbonate, magnesium carbonate, magnesium oxide and magnesium hydroxide
- Acidic reacting-agent such as those disclosed in US2003114494, notably sodium dihydrogen phosphate (NaH 2 PO 4 ), can also be used.
- the expression “exempt of alkaline-reacting compound” should be taken to mean a composition that substantially does not contain any alkaline-reacting compound, in other words a composition in which the amount of alkaline-reacting compound is not sufficient to set up an alkaline micro-environment around the active ingredient when it is in contact with an acid or neutral aqueous medium, for example a micro-environment having a pH above 7.
- said benzimidazole active ingredient is not in the form of an alkaline salt, and said composition is exempt of alkaline-reacting compounds.
- Mixtures of active ingredients are also envisaged, for example those comprising a benzimidazole in association with another active ingredient, or those containing two benzimidazoles.
- the core contains the benzimidazole active ingredient together with various excipients, notably diluents (also known as fillers) and disintegrant, and optionally lubricant.
- diluents also known as fillers
- the diluents will generally comprise a first diluent which is water-soluble, and optionally a second diluent which is water-insoluble (or hydrodispersible). These types of diluents are known in the art. They are crystalline or amorphous, and are generally inert with respect to the benzimidazole active ingredient.
- the first water-soluble diluent examples include lactose, mannitol, and mixtures thereof. Lactose is preferred.
- the second water-insoluble diluent examples include cellulose acetate, microcrystalline cellulose, and mixtures thereof. Cellulose acetate is preferred.
- the weight ratio first diluent to second diluent is preferably from about 1.5:1 to 1:1.5.
- the particle size of the first (and optionally second diluent) is not critical.
- the d 50 of the diluent particle is from about 50 ⁇ m to about 400 ⁇ m, preferably from about 75 ⁇ m to about 150 ⁇ m.
- the disintegrant can be any compound known in the art to that effect.
- examples of disintegrants are cross-linked polyvinylpyrrolidone (crospovidone), sodium croscarmellose, sodium carboxymethyl starch, modified starch or unmodified starch, colloidal silica and mixtures thereof.
- the preferred disintegrant is cross-linked polyvinylpyrrolidone (crospovidone).
- the lubricant can be selected from the group consisting of sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate and mixtures thereof.
- One exemplary core formulation is one where said core consists essentially of, by weight:
- Another exemplary core formulation is one where said core consists essentially of, by weight:
- the core consists essentially of the benzimidazole active ingredient, of the first, water-soluble diluent, optionally of the second, water-insoluble, diluent, of the disintegrant, and optionally of the lubricant.
- the core consists essentially of the benzimidazole active ingredient, of the first, water-soluble diluent, the disintegrant, and the lubricant.
- the term “consisting essentially of”, in one embodiment, is intended to mean that the listed compounds represent more than 90% by weight of the core, preferably more than 95% by weight of the core, most preferably more than 98% by weight of the core.
- excipients such as fillers, plastifiers, surfactants, pigments, wetting agents, etc. may also be present in the core or the additional layers, if need be.
- the excipients can be any one traditionally used in the art. For more details about these excipients, one can refer to the disclosure in “Handbook of pharmaceutical excipients”, American Pharmaceutical Association, 1994 ISBN 0 91730 66 8, by Wade A. and Weller P. Examples are polysorbate 80, sodium lauryl sulfate, colloidal silica, titanium dioxide, etc.
- the intermediate layer comprises of at least one sub-layer. It corresponds to one or several inert water-soluble layers or layers which rapidly disintegrate in an aqueous medium, containing inert pharmaceutical excipients.
- This layer comprises at least one polymer conventionally used in applications where a film is provided by coating such as: sugars, polyethyleneglycol, polyvinylpyrrolidone, polyvinyl alcohol), hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatine, etc.
- This intermediate layer is applied to the core using any coating technique conventionally employed in a suitable coating tank or in a fluidized bed device, with the use of suitable aqueous and/or organic solvents, or by using latex suspensions of said excipients.
- Water is the preferred solvent.
- film-forming polymers generally water-soluble polymers albeit water-insoluble polymers may be used
- plasticizers such as, for example, propylene glycol
- auxiliaries e.g. buffers, bases, pigments, surfactants, etc.
- additives and auxiliaries or excipients can be any one of the conventional pharmaceutical excipients cited in the section relating to the core, or a mixture thereof.
- Talc is one preferred excipient used in the intermediate layer.
- An exemplary composition for the intermediate layer comprises by weight, based on the weight of said layer:
- hydroxypropylmethylcellulose or another polymer such as PVP
- the enteric layer according to this invention corresponds to at least one sub-layer that is entero-soluble and gastro-resistant. It is applied to the intermediate layer by conventional coating techniques such as coating in a tank or a fluidized bed employing polymer solutions in water or in suitable organic solvents or using latex suspensions of these polymers. Water is the preferred solvent.
- the enteric coating can also be applied using aqueous dispersions of polymers. Water-soluble or water-insoluble polymers, or mixtures thereof can be used, according to methods known in the art. The expert knows, on the basis of his technical knowledge, what outer layers which are resistant to gastric juice can be used.
- cellulose phthalates and derivatives thereof use can be made of: cellulose phthalates and derivatives thereof, cellulose acetyl phthalate, hydroxypropyl-methylcellulose phthalate, polyvinyl phthalate acetate, as well as (meth)acrylic (co)polymers.
- acrylic copolymers one may cite especially the methacrylic acid/alkyl (meth)acrylate copolymers (sold as Eudragit®). A methyl radical and an ethyl radical are preferred as alkyl radical.
- the methacrylic acid type C copolymer complying with the US pharmacopoeia is one polymer suited.
- a preferred polymer is a copolymer based on methacrylic acid and ethyl acrylate, in which the ratio of free carboxyl groups to esters groups is about 1:1.
- the average molecular weight is, for example, about 250,000.
- Exemplary coating polymers are commercially available; they are those available as Aquateric® (FMC Corporation), CE5142 coating (BASF) and especially the Eudragit® products (Rohm Pharma), these latter being preferred.
- the enteric layer can also contain a pharmaceutically-acceptable plastifying agent such as, for example, ketanol, triacetine, citric acid esters (e.g. triethyl citrate) such as those known under as Citroflex® (Pfizer), phthalic acid esters, dibutylsuccinate, polyethyleneglycol of varying molecular weights, or any other similar plastifying agent.
- a pharmaceutically-acceptable plastifying agent such as, for example, ketanol, triacetine, citric acid esters (e.g. triethyl citrate) such as those known under as Citroflex® (Pfizer), phthalic acid esters, dibutylsuccinate, polyethyleneglycol of varying molecular weights, or any other similar plastifying agent.
- the amount of plastifying agent is in general optimized for each polymer and the plastifying agent generally represents by weight 1 to 30% of the polymer, for example from 5 to 25%.
- Supplementary agents such as talc, pigments, coloring agents, flavoring agents, as well as any other excipient that conventionally enters into the composition of enteric coatings can be employed; such other conventional excipients being e.g. those disclosed in connection with the core.
- Talc is one preferred excipient.
- An exemplary composition for the enteric layer comprises by weight, based on the weight of said layer:
- methacrylic acid/alkyl (meth)acrylate copolymer or another enteric polymer
- composition according to the present invention generally comprises, based on the total weight of the composition:
- a core representing about 70 to about 95% by weight, preferably about 70 to about 90% by weight;
- an intermediate layer representing about 5 to about 30% by weight, preferably about 8 to about 15% by weight;
- an enteric layer representing from about 3 to about 20% by weight, preferably about 5 to about 15% by weight.
- additional layers or sub-layers can be added, for the purposes of adding flavor and/or color, and/or improving acceptability of the medicament and/or allowing it to be marked.
- the process used to manufacture the instant composition is very simple. First a core is manufactured, and then the intermediate and enteric layers are coated on said core using any classical method.
- the present invention brings a novel manufacturing process as far as the core is concerned. It is important to note that the present process allows manufacturing the core without recourse to any binder.
- the core is generally manufactured as follows. In a first step, the various ingredients are granulated together. In a second step, a tablet is obtained starting from the granulates obtained at the first step by compressing the product.
- the first granulating step can be carried out by using any granulating method, such as dry granulation, sieving, fluidized bed granulation or wet granulation.
- any granulating method such as dry granulation, sieving, fluidized bed granulation or wet granulation.
- fluidized bed granulation and wet granulation one uses suitable aqueous and/or organic solvents, preferably an aqueous solvent.
- Wet granulation is the preferred method.
- the apparatus that can be used is for example a high shear mixer.
- the disintegrant used in the composition can be partly into the granulate and partly in the outer phase.
- the weight ratio distribution granulate:outer phase of the disintegrant can be from 100:0 to 0:100, especially 70:30 to 0:100.
- the process for manufacturing the core comprises the following sub-steps:
- the drying step can be carried out in any conventional apparatus known to that effect, for example a fluidized bed or a drying oven.
- the drying step is considered as having been carried out when the residual water content is below 10%, for example below 3%, depending on the kind and amount of ingredients. Tableting then follows granulation.
- the tableting step can be implemented using any conventional technique which is suitable, for example using alternating or rotating compressing equipment.
- the core can be obtained by direct, dry, compression,
- the water, if used, needed to produce the core is generally present in an amount of from 10% to 100% of the core weight.
- the water needed to produce the intermediate layer and/or the enteric layer is generally present in an amount of from 100% to 1000% of the intermediate and/or enteric layer weight.
- the composition according to the invention is provided in a single tablet form (which may be breakable, if need be).
- the composition is in the form of micro-tablets enclosed inside a capsule, e.g. a gelatin capsule.
- a gelatin capsule any gelatin capsule conventionally employed in the pharmaceutical formulation field can be used, such as the hard gelatin capsule known as Capsugel®, available from Eli Lilly.
- the compositions of this invention are particularly suitable for oral administration of the active ingredients and are particularly suitable for treating gastro-intestinal sicknesses.
- Active ingredient, lactose and cellulose acetate are dry mixed. Water is added and granulation is carried out in a gravity funnel. Granulates are dried at 55° C. for 45 minutes. Crospovidone and glyceryl behenate are then added and mixed. The resulting mixture is then compressed into tablets (using a BetaPress® from Manesty with a punch having a curvature and a diameter of 7 mm—also known as 7R7).
- HPMC HPMC is dissolved in the water, and talc and titanium dioxide are then added.
- the suspension is homogenized and sprayed onto the tableted core in a coating pan (vector corporation perforated pan coater type LDCS).
- the following enteric coating layer formulation is used.
- Triethyl citrate is dissolved in 60% of the water. The resulting solution is added to the Eudragit polymer and let in contact for 45 minutes under low stirring. Talc is added to the remaining 40% water, and the suspension is homogenized. Both compositions are then combined into one solution which is sprayed onto the intermediate coated core in a coating pan (identical to the one used for the intermediate layer) using a peristaltic pump and a spray nozzle (available from company spray systems).
- the process is as in example 1.
- the process differs in that half of crospovidone is mixed to form the granulates and half is mixed with the granulates as in example
- the intermediate and enteric layers are as in example 1 and the process for coating is the same.
Abstract
Description
- The invention relates to a novel composition comprising a benzimidazole, said composition being notably free of any binder. The invention also relates to a very simple process for the manufacture of the present composition.
- Benzimidazoles are known proton pump inhibitors. Representatives of this class of drugs are omeprazole, esomeprazole, pantoprazole, rabeprazole. Many formulation patents are known for this type of active pharmaceutical ingredient. WO-A-9712581 discloses a composition exempt of alkaline-reacting compounds comprising:
- (a) a core containing a benzimidazole active ingredient, said core being constituted of nuclei and said active ingredient mixed together and then compressed together, and said active ingredient not being in the form of an alkaline salt, and where a polymer acting as a binder is generally used in the core manufacture;
- (b) an intermediate layer; and
- (c) an enteric layer applied onto the intermediate layer.
- U.S. Pat. No. 5,997,903 discloses a medicament in pellet or tablet form which contains the active compound pantoprazole, which is to be administered orally, is resistant to gastric juice and consists of a basic pellet core or tablet core, one or more inert, water-soluble intermediate layer(s) and an outer layer which is resistant to gastric juice, and which is characterized in that the core contains, in addition to pantoprazole or in addition to a pantoprazole salt, polyvinylpyrrolidone and/or hydroxypropylmethylcellulose as the binder, and if desired mannitol additionally as an inert filler. US2003114494 discloses a stable oral pharmaceutical which comprises a benzimidazole, comprising:
- (a) an inert core;
- (b) thereon an active ingredient layer which comprises the benzimidazole mixed with an acidic reacting compound and, where appropriate, pharmaceutically acceptable adjuvants among which binders (water-soluble polymers) which are always used in this document;
- (c) at least one inert layer; and
- (d) an enteric layer applied onto said at least one inert layer.
- Albeit “tablet” is mentioned in this latter document, the tablet form is only mentioned and is not exemplified; this document is in fact essentially towards the pellet form.
- There is still a need for a composition which can be either alkaline free or not, or even can contain an acidic compound, and which would be easy to manufacture, notably without having to revert to any binder. None of the above documents teaches or suggests the instant invention.
- The invention provides new benzimidazole compositions, especially the following compositions:
- A composition comprising a benzimidazole active ingredient, said composition comprising:
-
- (a) a core containing said benzimidazole active ingredient;
- (b) an intermediate layer; and
- (c) an enteric layer;
- said core being substantially free of binder; or said core being substantially free of PVP and of HPMC.
- A composition comprising a benzimidazole active ingredient, said composition comprising:
-
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- about 10 to about 80 parts of said benzimidazole active ingredient,
- about 20 to about 85 parts of a first, water-soluble, diluent,
- about 0 to about 80 parts of a second, water-insoluble, diluent,
- about 10 to about 40 parts of a disintegrant; and
- 0 to about 5 parts of a lubricant;
- (b) an intermediate layer; and
- (c) an enteric layer.
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- A composition comprising a benzimidazole active ingredient, said composition comprising:
-
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- about 15 to about 60 parts of said benzimidazole active ingredient,
- about 40 to about 75 parts of lactose,
- about 15 to about 30 parts of a disintegrant, and
- about 0.5 to about 5 parts of a lubricant;
- (b) an intermediate layer; and
- (c) an enteric layer,
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- A composition comprising a benzimidazole active ingredient not being in the form of an alkaline salt, said composition being exempt of alkaline-reacting compounds, said composition comprising:
-
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- about 15 to about 60 parts of said benzimidazole active ingredient,
- about 40 to about 75 parts of a first, water-soluble, diluent,
- about 0 to about 40 parts of a second, water-insoluble, diluent,
- about 15 to about 30 parts of a disintegrant, and about 0.5 to about 5 parts of a lubricant;
- (b) an intermediate layer; and
- (c) an enteric layer. A composition comprising omeprazole or esomeprazole or pantoprazole or lansoprazole or rabeprazole, said composition comprising:
- (a) a core containing said omeprazole or esomeprazole or pantoprazole or lansoprazole or rabeprazole, where said core consists essentially of, by weight:
- about 15 to about 60 parts of said omeprazole or esomeprazole or pantoprazole or lansoprazole or rabeprazole,
- about 40 to about 75 parts of lactose,
- about 15 to about 30 parts of a disintegrant, and
- about 0.5 to about 5 parts of a lubricant;
- (b) an intermediate layer; and
- (c) an enteric layer.
- (a) a core containing said benzimidazole active ingredient, where said core consists essentially of, by weight:
- The invention also provides a process for manufacturing the compositions of the invention, said process comprising the steps of: (i) granulating said active ingredient with said diluents, said disintegrant and said lubricant if any; (ii) compressing the product of step (i) to form a tablet core containing an active ingredient; (iii) coating said core with said intermediate layer; and (iv) coating a product from step (iii) with said enteric layer.
- The invention is designed for any benzimidazole, which is a class of compounds that is generally known. Here, the expression “benzimidazole active ingredient” should be taken to mean benzimidazole derivatives that are of therapeutic value. The benzimidazole active ingredients as used in the instant application are notably, but not limitatively, disclosed in the following patents and patent applications: EP-A-0,005,129, EP-A-0,080,602, EP-A-0,127,763, EP-A-0,130,729, EP-A-0,134,400, EP-A-0,146,370, EP-A-0,150,586, EP-A-0,166,287, EP-A-0,173,664, EP-A-0,244,380, DE-3,415,971, GB-A-2,082,580, GB-A-2,141,429, GB-A-2163747, U.S. Pat. No. 4,045,563, U.S. Pat. No. 4,182,766, U.S. Pat. No. 4,255,431, U.S. Pat. No. 4,337,257, U.S. Pat. No. 4,508,905, U.S. Pat. No. 4,628,098, U.S. Pat. No. 4,689,333, U.S. Pat. No. 4,734,416, U.S. Pat. No. 4,738,974, U.S. Pat. No. 4,758,579, U.S. Pat. No. 4,736,505, U.S. Pat. No. 4,853,230, U.S. Pat. No. 5,006,528, U.S. Pat. No. 5,013,743, U.S. Pat. No. 5,026,560, U.S. Pat. No. 5,035,899, U.S. Pat. No. 5,039,806, U.S. Pat. No. 5,045,321, U.S. Pat. No. 5,045,552, U.S. Pat. No. 5,093,132, U.S. Pat. No. 5,433,959, U.S. Pat. No. 5,690,960, U.S. Pat. No. 5,714,504, U.S. Pat. No. 5,877,192, U.S. Pat. No. 5,900,424, U.S. Pat. No. 5,997,903, U.S. Pat. No. 6,147,103, U.S. Pat. No. 6,150,380, U.S. Pat. No. 6,166,213, U.S. Pat. No. 6,191,148, U.S. Pat. No. 6,369,085, and U.S. Pat. No. 6,428,810. The instant invention notably applies to omeprazole, esomeprazole, pantoprazole, lansoprazole, leminoprazole, pariprazole, rabeprazole, timoprazole, aripiprazole and diapiprazole.
- The alkaline salt form or derivative of the active ingredients cited above is also suitable in one embodiment. Derivatives, such as salts (hydrates such as sesquihydrates, etc.), alkaline salts (salts formed with lithium, sodium, magnesium, potassium, calcium etc. as well as any other base), esters and the like (including pro-drugs), are also contemplated. It is also possible to use an alkaline-reacting agent together with the benzimidazole active ingredient. Examples of such agents which may be mentioned here are the pharmacologically tolerated alkali metal, alkaline earth metal or earth metal salts of weak acids and the pharmacologically tolerated hydroxides and oxides of alkaline earth and earth metals, such as sodium carbonate, calcium carbonate, magnesium carbonate, magnesium oxide and magnesium hydroxide, Acidic reacting-agent such as those disclosed in US2003114494, notably sodium dihydrogen phosphate (NaH2PO4), can also be used.
- Here, the expression “exempt of alkaline-reacting compound” should be taken to mean a composition that substantially does not contain any alkaline-reacting compound, in other words a composition in which the amount of alkaline-reacting compound is not sufficient to set up an alkaline micro-environment around the active ingredient when it is in contact with an acid or neutral aqueous medium, for example a micro-environment having a pH above 7. In one embodiment, said benzimidazole active ingredient is not in the form of an alkaline salt, and said composition is exempt of alkaline-reacting compounds. Mixtures of active ingredients are also envisaged, for example those comprising a benzimidazole in association with another active ingredient, or those containing two benzimidazoles.
- The core contains the benzimidazole active ingredient together with various excipients, notably diluents (also known as fillers) and disintegrant, and optionally lubricant. The diluents will generally comprise a first diluent which is water-soluble, and optionally a second diluent which is water-insoluble (or hydrodispersible). These types of diluents are known in the art. They are crystalline or amorphous, and are generally inert with respect to the benzimidazole active ingredient.
- Examples of the first water-soluble diluent are lactose, mannitol, and mixtures thereof. Lactose is preferred. Examples of the second water-insoluble diluent, if used, are cellulose acetate, microcrystalline cellulose, and mixtures thereof. Cellulose acetate is preferred. When the composition comprises a first diluent and a second diluent, the weight ratio first diluent to second diluent is preferably from about 1.5:1 to 1:1.5. The particle size of the first (and optionally second diluent) is not critical. In general, the d50 of the diluent particle is from about 50 μm to about 400 μm, preferably from about 75 μm to about 150 μm.
- The disintegrant can be any compound known in the art to that effect. Examples of disintegrants are cross-linked polyvinylpyrrolidone (crospovidone), sodium croscarmellose, sodium carboxymethyl starch, modified starch or unmodified starch, colloidal silica and mixtures thereof. The preferred disintegrant is cross-linked polyvinylpyrrolidone (crospovidone). The lubricant can be selected from the group consisting of sodium stearylfumarate, magnesium stearate, talc, glyceryl behenate and mixtures thereof.
- These compounds are used in varying amounts. Exemplary amounts are:
- about 10 to about 80 parts, preferably about 15 to about 60 parts of said benzimidazole active ingredient;
- about 20 to about 85 parts, preferably about 40 to about 75 parts, of said first, water-soluble, diluent;
- about 0 to about 80 parts, preferably about 0 to about 40 parts, of said second, water-insoluble, diluent, and most preferably no second, water-insoluble, diluent is used;
- about 10 to about 40 parts, preferably about 15 to about 30 parts, of said disintegrant;
- 0 to about 5 parts, preferably about 0.5 to about 5 parts, of said lubricant.
- One exemplary core formulation is one where said core consists essentially of, by weight:
- about 15 to about 60 parts of said benzimidazole active ingredient,
- about 40 to about 75 parts of lactose,
- about 15 to about 30 parts of a disintegrant, and
- about 0.5 to about 5 parts of a lubricant.
- Another exemplary core formulation is one where said core consists essentially of, by weight:
- about 15 to about 60 parts of said benzimidazole active ingredient,
- about 30 to about 60 parts of lactose,
- about 30 to about 60 parts of cellulose acetate,
- about 15 to about 30 parts of a disintegrant, and
- about 0.5 to about 5 parts of a lubricant,
- In one embodiment, the core consists essentially of the benzimidazole active ingredient, of the first, water-soluble diluent, optionally of the second, water-insoluble, diluent, of the disintegrant, and optionally of the lubricant. In another, preferred embodiment, the core consists essentially of the benzimidazole active ingredient, of the first, water-soluble diluent, the disintegrant, and the lubricant. The term “consisting essentially of”, in one embodiment, is intended to mean that the listed compounds represent more than 90% by weight of the core, preferably more than 95% by weight of the core, most preferably more than 98% by weight of the core.
- Other excipients such as fillers, plastifiers, surfactants, pigments, wetting agents, etc. may also be present in the core or the additional layers, if need be. The excipients can be any one traditionally used in the art. For more details about these excipients, one can refer to the disclosure in “Handbook of pharmaceutical excipients”, American Pharmaceutical Association, 1994 ISBN 0 91730 66 8, by Wade A. and Weller P. Examples are polysorbate 80, sodium lauryl sulfate, colloidal silica, titanium dioxide, etc.
- The intermediate layer, according to the invention comprises of at least one sub-layer. It corresponds to one or several inert water-soluble layers or layers which rapidly disintegrate in an aqueous medium, containing inert pharmaceutical excipients. This layer comprises at least one polymer conventionally used in applications where a film is provided by coating such as: sugars, polyethyleneglycol, polyvinylpyrrolidone, polyvinyl alcohol), hydroxypropylcellulose, hydroxymethylcellulose, hydroxypropylmethylcellulose, gelatine, etc. This intermediate layer is applied to the core using any coating technique conventionally employed in a suitable coating tank or in a fluidized bed device, with the use of suitable aqueous and/or organic solvents, or by using latex suspensions of said excipients. Water is the preferred solvent. Examples which may be mentioned of film-forming polymers (generally water-soluble polymers albeit water-insoluble polymers may be used) which can be used advantageously for the intermediate layer are given above, and especially hydroxypropylmethylcellulose and/or polyvinylpyrrolidone, to which plasticizers (such as, for example, propylene glycol) and/or other additives and auxiliaries (e.g. buffers, bases, pigments, surfactants, etc.) can also be added if desired. These other additives and auxiliaries or excipients can be any one of the conventional pharmaceutical excipients cited in the section relating to the core, or a mixture thereof. Talc is one preferred excipient used in the intermediate layer.
- An exemplary composition for the intermediate layer comprises by weight, based on the weight of said layer:
- about 30% to about 80%, preferably about 50% to about 70%, of hydroxypropylmethylcellulose (or another polymer such as PVP);
- about 15% to about 50%, preferably about 20% to about 40%, of talc;
- about 3% to about 25%, preferably about 5% to about 15%, of titanium dioxide.
- The enteric layer according to this invention corresponds to at least one sub-layer that is entero-soluble and gastro-resistant. It is applied to the intermediate layer by conventional coating techniques such as coating in a tank or a fluidized bed employing polymer solutions in water or in suitable organic solvents or using latex suspensions of these polymers. Water is the preferred solvent. The enteric coating can also be applied using aqueous dispersions of polymers. Water-soluble or water-insoluble polymers, or mixtures thereof can be used, according to methods known in the art. The expert knows, on the basis of his technical knowledge, what outer layers which are resistant to gastric juice can be used.
- As a polymer, use can be made of: cellulose phthalates and derivatives thereof, cellulose acetyl phthalate, hydroxypropyl-methylcellulose phthalate, polyvinyl phthalate acetate, as well as (meth)acrylic (co)polymers. As acrylic copolymers, one may cite especially the methacrylic acid/alkyl (meth)acrylate copolymers (sold as Eudragit®). A methyl radical and an ethyl radical are preferred as alkyl radical. The methacrylic acid type C copolymer complying with the US pharmacopoeia is one polymer suited. A preferred polymer is a copolymer based on methacrylic acid and ethyl acrylate, in which the ratio of free carboxyl groups to esters groups is about 1:1. The average molecular weight is, for example, about 250,000. Exemplary coating polymers are commercially available; they are those available as Aquateric® (FMC Corporation), CE5142 coating (BASF) and especially the Eudragit® products (Rohm Pharma), these latter being preferred.
- The enteric layer can also contain a pharmaceutically-acceptable plastifying agent such as, for example, ketanol, triacetine, citric acid esters (e.g. triethyl citrate) such as those known under as Citroflex® (Pfizer), phthalic acid esters, dibutylsuccinate, polyethyleneglycol of varying molecular weights, or any other similar plastifying agent. The amount of plastifying agent is in general optimized for each polymer and the plastifying agent generally represents by weight 1 to 30% of the polymer, for example from 5 to 25%. Supplementary agents such as talc, pigments, coloring agents, flavoring agents, as well as any other excipient that conventionally enters into the composition of enteric coatings can be employed; such other conventional excipients being e.g. those disclosed in connection with the core. Talc is one preferred excipient.
- An exemplary composition for the enteric layer comprises by weight, based on the weight of said layer:
- about 50% to about 90%, preferably about 60% to about 85%, of methacrylic acid/alkyl (meth)acrylate copolymer (or another enteric polymer);
- about 3% to about 25%, preferably about 5% to about 15%, of triethyl citrate (or another plastifying agent);
- about 5% to about 30%, preferably about 10% to about 20%, of talc.
- The composition according to the present invention generally comprises, based on the total weight of the composition:
- a core representing about 70 to about 95% by weight, preferably about 70 to about 90% by weight;
- an intermediate layer representing about 5 to about 30% by weight, preferably about 8 to about 15% by weight;
- an enteric layer representing from about 3 to about 20% by weight, preferably about 5 to about 15% by weight.
- It should be noted that additional layers or sub-layers can be added, for the purposes of adding flavor and/or color, and/or improving acceptability of the medicament and/or allowing it to be marked.
- The process used to manufacture the instant composition is very simple. First a core is manufactured, and then the intermediate and enteric layers are coated on said core using any classical method. The present invention brings a novel manufacturing process as far as the core is concerned. It is important to note that the present process allows manufacturing the core without recourse to any binder.
- The core is generally manufactured as follows. In a first step, the various ingredients are granulated together. In a second step, a tablet is obtained starting from the granulates obtained at the first step by compressing the product.
- The first granulating step can be carried out by using any granulating method, such as dry granulation, sieving, fluidized bed granulation or wet granulation. In the case of fluidized bed granulation and wet granulation, one uses suitable aqueous and/or organic solvents, preferably an aqueous solvent. Wet granulation is the preferred method. The apparatus that can be used is for example a high shear mixer. It should be noted that the disintegrant used in the composition can be partly into the granulate and partly in the outer phase. The weight ratio distribution granulate:outer phase of the disintegrant can be from 100:0 to 0:100, especially 70:30 to 0:100.
- In one preferred embodiment, the process for manufacturing the core comprises the following sub-steps:
- (a) dry mixing said benzimidazole active ingredient, said first diluent and optionally said second diluent and optionally part of said disintegrant;
- (b) granulating the product of sub-step (a) with water;
- (c) drying the granulates of sub-step (b); and
- (d) dry mixing the dried granulates of sub-step (c) with said disintegrant or the remainder thereof and said lubricant.
- The drying step can be carried out in any conventional apparatus known to that effect, for example a fluidized bed or a drying oven. The drying step is considered as having been carried out when the residual water content is below 10%, for example below 3%, depending on the kind and amount of ingredients. Tableting then follows granulation. The tableting step can be implemented using any conventional technique which is suitable, for example using alternating or rotating compressing equipment. In another, less preferred, embodiment, the core can be obtained by direct, dry, compression,
- The water, if used, needed to produce the core is generally present in an amount of from 10% to 100% of the core weight. The water needed to produce the intermediate layer and/or the enteric layer is generally present in an amount of from 100% to 1000% of the intermediate and/or enteric layer weight.
- In one preferred embodiment, the composition according to the invention is provided in a single tablet form (which may be breakable, if need be). In another embodiment, the composition is in the form of micro-tablets enclosed inside a capsule, e.g. a gelatin capsule. For this, any gelatin capsule conventionally employed in the pharmaceutical formulation field can be used, such as the hard gelatin capsule known as Capsugel®, available from Eli Lilly. The compositions of this invention are particularly suitable for oral administration of the active ingredients and are particularly suitable for treating gastro-intestinal sicknesses.
- The following examples illustrate the invention without limiting it.
- The following core formulations are prepared.
-
Amount (mg/unit) Compound Ex. 1A Ex. 1B Rabeprazole Na 20.10 — Pantoprazole Na Sesquihydrate — 45.10 Lactose 200mesh 44.00 44.00 Cellulose Acetate 44.00 44.00 Glyceryl behenate 1.50 1.50 Crospovidone 22.40 22.40 Water* 40.00 40.00 Total (dry) 131.90 157.00 *evaporates off during process - Active ingredient, lactose and cellulose acetate are dry mixed. Water is added and granulation is carried out in a gravity funnel. Granulates are dried at 55° C. for 45 minutes. Crospovidone and glyceryl behenate are then added and mixed. The resulting mixture is then compressed into tablets (using a BetaPress® from Manesty with a punch having a curvature and a diameter of 7 mm—also known as 7R7).
- The following intermediate layer formulation is used.
-
Compound Amount (mg/unit) HPMC 3 cp 11.75 Titanium dioxide 2.35 Talc 5.90 Water* 100 Total 20.00 *evaporates off during process - HPMC is dissolved in the water, and talc and titanium dioxide are then added. The suspension is homogenized and sprayed onto the tableted core in a coating pan (vector corporation perforated pan coater type LDCS).
- The following enteric coating layer formulation is used.
-
Compound Amount (mg/unit) Eudragit ® L30D 11.10 Talc 2.23 Triethyl citrate 1.67 Water* 44 Total 15.00 *evaporates off during process - Triethyl citrate is dissolved in 60% of the water. The resulting solution is added to the Eudragit polymer and let in contact for 45 minutes under low stirring. Talc is added to the remaining 40% water, and the suspension is homogenized. Both compositions are then combined into one solution which is sprayed onto the intermediate coated core in a coating pan (identical to the one used for the intermediate layer) using a peristaltic pump and a spray nozzle (available from company spray systems).
- The following core formulations are prepared.
-
Amount (mg/unit) Compound Ex. 2A Ex. 2B Rabeprazole Na 20.00 — Pantoprazole Na Sesquihydrate — 45.10 Lactose 200mesh 88.00 88.00 Glyceryl behenate 1.50 3.00 Crospovidone 22.00 22.90 Water* 40.00 20.00 Total (dry) 131.50 159.00 *evaporates off during process - For example 2A, the process is as in example 1. For example 2B, the process differs in that half of crospovidone is mixed to form the granulates and half is mixed with the granulates as in example The intermediate and enteric layers are as in example 1 and the process for coating is the same.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/633,766 US20150164817A1 (en) | 2004-07-29 | 2015-02-27 | Composition comprising a benzimidazole and process for its manufacture |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/901,898 US20060024362A1 (en) | 2004-07-29 | 2004-07-29 | Composition comprising a benzimidazole and process for its manufacture |
US13/895,492 US8968776B2 (en) | 2004-07-29 | 2013-05-16 | Composition comprising a benzimidazole and process for its manufacture |
US14/633,766 US20150164817A1 (en) | 2004-07-29 | 2015-02-27 | Composition comprising a benzimidazole and process for its manufacture |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/895,492 Continuation US8968776B2 (en) | 2004-07-29 | 2013-05-16 | Composition comprising a benzimidazole and process for its manufacture |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150164817A1 true US20150164817A1 (en) | 2015-06-18 |
Family
ID=35732527
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/901,898 Abandoned US20060024362A1 (en) | 2004-07-29 | 2004-07-29 | Composition comprising a benzimidazole and process for its manufacture |
US13/895,492 Expired - Fee Related US8968776B2 (en) | 2004-07-29 | 2013-05-16 | Composition comprising a benzimidazole and process for its manufacture |
US14/633,766 Abandoned US20150164817A1 (en) | 2004-07-29 | 2015-02-27 | Composition comprising a benzimidazole and process for its manufacture |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/901,898 Abandoned US20060024362A1 (en) | 2004-07-29 | 2004-07-29 | Composition comprising a benzimidazole and process for its manufacture |
US13/895,492 Expired - Fee Related US8968776B2 (en) | 2004-07-29 | 2013-05-16 | Composition comprising a benzimidazole and process for its manufacture |
Country Status (1)
Country | Link |
---|---|
US (3) | US20060024362A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (en) | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation |
DE10359528A1 (en) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S) -2-N-propylamino-5-hydroxytetralin as a D3 agonist therapeutic |
JP5563735B2 (en) | 2004-06-16 | 2014-07-30 | タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド | PPI multiple dosage form |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
BRPI0621024A2 (en) * | 2006-01-16 | 2011-11-29 | Jubilant Organosys Ltd | stable pharmaceutical formulation of a labile acid compound and the process for preparing it |
ITMI20062290A1 (en) * | 2006-11-28 | 2008-05-29 | Monteres S R L | TABLETS STABLE WITH STORAGE BASED ON BENZIMIDAZOLE DERIVATIVES COATED WITH GASTRO-RESISTANT FILM |
US8173158B2 (en) * | 2007-10-12 | 2012-05-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treating gastrointestinal disorders independent of the intake of food |
JP5455438B2 (en) * | 2008-06-06 | 2014-03-26 | 株式会社東芝 | Mask pattern data creation method |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
ME03053B (en) | 2009-12-22 | 2018-10-20 | Ucb Biopharma Sprl | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
WO2011140446A2 (en) * | 2010-05-06 | 2011-11-10 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations |
AR089765A1 (en) | 2012-01-23 | 2014-09-17 | Bayer Oy | A SYSTEM FOR THE SUPPLY OF A PHARMACO |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US118647A (en) * | 1871-08-29 | Improvement in journal-boxes | ||
US9496A (en) * | 1852-12-21 | Method of measuring cloth on the cloth-beam | ||
US92597A (en) * | 1869-07-13 | Improved counterpoise gun-carriage | ||
US86567A (en) * | 1869-02-02 | Improved brick-machine | ||
US59466A (en) * | 1866-11-06 | Improved school desk and seat | ||
US161461A (en) * | 1875-03-30 | Improvement in apparatus for breaking horses | ||
US176465A (en) * | 1876-04-25 | Improvement in plows | ||
US91634A (en) * | 1869-06-22 | Improvement in screw-driver | ||
US58005A (en) * | 1866-09-11 | Improvement in distilling petroleum and other liquids | ||
US170302A (en) * | 1875-11-23 | Improvement in iron fences | ||
US57997A (en) * | 1866-09-11 | Improvement in malt-ksln floors | ||
US57998A (en) * | 1866-09-11 | Improvement in broom-heads | ||
US104060A (en) * | 1870-06-07 | Improvement in organ-bellows | ||
US224949A (en) * | 1880-02-24 | Method of printing on textile fabrics | ||
US57999A (en) * | 1866-09-11 | Improved composition for roofing | ||
US162320A (en) * | 1875-04-20 | Improvement in automatic fans | ||
US35834A (en) * | 1862-07-08 | Improvement in counterfelt-cqin detectors | ||
SE416649B (en) * | 1974-05-16 | 1981-01-26 | Haessle Ab | PROCEDURE FOR THE PREPARATION OF SUBSTANCES WHICH PREVENT Gastric acid secretion |
IN148930B (en) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche | |
JPS54130587A (en) * | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
SE7804231L (en) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
CH644116A5 (en) | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | IMIDAZOLE DERIVATIVES. |
US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
SE8300736D0 (en) * | 1983-02-11 | 1983-02-11 | Haessle Ab | NOVEL PHARMACOLOGICALLY ACTIVE COMPOUNDS |
SE8301182D0 (en) * | 1983-03-04 | 1983-03-04 | Haessle Ab | NOVEL COMPOUNDS |
IL71664A (en) | 1983-05-03 | 1987-11-30 | Byk Gulden Lomberg Chem Fab | Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same |
DE3415971A1 (en) | 1983-05-03 | 1984-11-08 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Acylated benzimidazoles, processes for their preparation, their use and medicaments containing them |
HU193408B (en) * | 1983-05-03 | 1987-10-28 | Byk Gulden Lomberg Chem Fqb | Process for production of new tree-cycle compounds |
GR81595B (en) | 1983-06-18 | 1984-12-11 | Wyeth John & Brother Ltd | |
CA1259070A (en) | 1983-07-01 | 1989-09-05 | Upjohn Company (The) | Substituted 2-¬monoannelated(3,4-,4,5-, and 5,6-)- pyridylalkylenesulfinyl|-benzimidazoles |
US4575554A (en) | 1983-12-05 | 1986-03-11 | The Upjohn Company | Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents |
IE57646B1 (en) | 1983-12-16 | 1993-02-10 | Wyeth John & Brother Ltd | Derivatives of imidazoquinolines and analogues thereof |
EP0159144B1 (en) | 1984-02-27 | 1989-06-07 | Niigata Engineering Co., Ltd. | Azimuth thruster for use in ships |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
US4721709A (en) * | 1984-07-26 | 1988-01-26 | Pyare Seth | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions |
SE8404065D0 (en) | 1984-08-10 | 1984-08-10 | Haessle Ab | NOVEL BIOLOGICALLY ACTIVE COMPOUNDS |
JPS6150978A (en) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
US5433959A (en) * | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
CH672888A5 (en) * | 1986-11-07 | 1990-01-15 | Mepha Ag | |
FI90544C (en) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Process for Preparation as Drug Useful 2-Pyridin-2-yl-methylthio- and sulfinyl-1H-benzimidazole derivatives |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
CH668553A5 (en) * | 1987-02-02 | 1989-01-13 | Mepha Ag | MEDICINAL PRODUCTS WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE. |
JPH0768125B2 (en) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | Oral formulation of acid labile compounds |
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
ATE114114T1 (en) * | 1989-02-10 | 1994-12-15 | Takeda Chemical Industries Ltd | USE OF BENZIMIDAZOLE DERIVATIVES AS ANTIBACTERIAL AGENTS. |
JP2508298B2 (en) * | 1989-10-18 | 1996-06-19 | 日本電気株式会社 | Digital signal receiving system and receiving apparatus |
YU48263B (en) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT |
SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
US5877192A (en) * | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
SE9302395D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | NEW PHARMACEUTICAL FORMULATION |
SE9302396D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
JP3350054B2 (en) * | 1994-07-08 | 2002-11-25 | アストラゼネカ・アクチエボラーグ | Multi-unit tableted dosage form (I) |
FR2723536A1 (en) * | 1994-08-11 | 1996-02-16 | Seth Pawan | COMPOSITION FOR SELECTIVE RELEASE OF AN ACTIVE INGREDIENT |
US6117453A (en) * | 1995-04-14 | 2000-09-12 | Pharma Pass | Solid compositions containing polyethylene oxide and an active ingredient |
US6348469B1 (en) * | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
NZ318501A (en) | 1995-09-21 | 1999-06-29 | Pharma Pass Llc | Novel composition containing an acid-labile omeprazole and process for its preparation |
US6048547A (en) * | 1996-04-15 | 2000-04-11 | Seth; Pawan | Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient |
FR2758459B1 (en) * | 1997-01-17 | 1999-05-07 | Pharma Pass | FENOFIBRATE PHARMACEUTICAL COMPOSITION HAVING HIGH BIODAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
US6166213A (en) * | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
US6191148B1 (en) * | 1998-08-11 | 2001-02-20 | Merck & Co., Inc. | Omerazole process and compositions thereof |
US6033686A (en) * | 1998-10-30 | 2000-03-07 | Pharma Pass Llc | Controlled release tablet of bupropion hydrochloride |
US6096341A (en) * | 1998-10-30 | 2000-08-01 | Pharma Pass Llc | Delayed release tablet of bupropion hydrochloride |
SE9803772D0 (en) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
UA72748C2 (en) | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
DE19959419A1 (en) * | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation |
US20030035834A1 (en) | 2000-05-26 | 2003-02-20 | Pawan Seth | Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
US6338857B1 (en) * | 2000-05-26 | 2002-01-15 | Pharma Pass Llc | Sustained release carbamazepine pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
US6350471B1 (en) * | 2000-05-31 | 2002-02-26 | Pharma Pass Llc | Tablet comprising a delayed release coating |
WO2002045694A1 (en) | 2000-12-07 | 2002-06-13 | Altana Pharma Ag | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
US6960357B2 (en) * | 2001-05-25 | 2005-11-01 | Mistral Pharma Inc. | Chemical delivery device |
US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
US20030059466A1 (en) | 2001-09-14 | 2003-03-27 | Pawan Seth | Delayed release tablet of venlafaxin |
US20030091634A1 (en) | 2001-09-14 | 2003-05-15 | Pawan Seth | Delayed release tablet of venlafaxin |
US20030118647A1 (en) | 2001-12-04 | 2003-06-26 | Pawan Seth | Extended release tablet of metformin |
US20050182056A9 (en) | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US20040086567A1 (en) | 2002-10-30 | 2004-05-06 | Pawan Seth | Bioequivalent composition of itraconazole and a hydrophilic polymer |
US20040162320A1 (en) | 2003-02-14 | 2004-08-19 | Pawan Seth | Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant |
US20040176465A1 (en) | 2003-03-07 | 2004-09-09 | Pawan Seth | Solid compositions containing fluoxetine and a coating |
CA2558535A1 (en) * | 2004-03-03 | 2005-10-06 | Teva Pharmaceutical Industries Ltd. | A stable pharmaceutical composition comprising an acid labile drug |
US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
-
2004
- 2004-07-29 US US10/901,898 patent/US20060024362A1/en not_active Abandoned
-
2013
- 2013-05-16 US US13/895,492 patent/US8968776B2/en not_active Expired - Fee Related
-
2015
- 2015-02-27 US US14/633,766 patent/US20150164817A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130251791A1 (en) | 2013-09-26 |
US8968776B2 (en) | 2015-03-03 |
US20060024362A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8968776B2 (en) | Composition comprising a benzimidazole and process for its manufacture | |
JP3878669B2 (en) | Multi-unit formulations containing proton pump inhibitors | |
CA2251430C (en) | Omeprazole formulation | |
US7488497B2 (en) | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID | |
US20090208575A1 (en) | Pharmaceutical Composition Of Acid Labile Substances | |
US20040213847A1 (en) | Delayed release pharmaceutical compositions containing proton pump inhibitors | |
US8865212B2 (en) | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same | |
HU226580B1 (en) | Pharmaceutical formulation comprising a 2-[[(2-pyridinyl)methyl]sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation | |
US6602522B1 (en) | Pharmaceutical formulation for acid-labile compounds | |
WO2010041276A1 (en) | Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof | |
US20130122090A1 (en) | Multiple Unit Tablet Composition | |
US8658216B2 (en) | Stable oral benzimidazole compositions and process of preparation thereof | |
WO2009060064A2 (en) | Pharmaceutical formulations for the oral administration of ppi | |
EP2345408A2 (en) | Acid labile drug formulations | |
WO2005034924A1 (en) | Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation | |
WO2004098573A1 (en) | An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation | |
EP1594479A1 (en) | Stable oral benzimidazole compositions and processes for their preparation | |
EP3236952B1 (en) | Pharmaceutical tablet composition | |
US8911787B2 (en) | Stable oral benzimidazole compositions and process of preparation thereof | |
US20080279951A1 (en) | Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process | |
US20030228363A1 (en) | Stabilized pharmaceutical compositons containing benzimidazole compounds | |
WO2006111853A2 (en) | Stable solid dosage forms of acid labile drug | |
CA2547398A1 (en) | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating | |
US20240033224A1 (en) | Enteric-coated pellet, method for preparing same and formulation comprising same | |
WO2006085723A1 (en) | The enteric coated pharmaceutical oral formulations comprising acid-labile active substances, and a method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KREMERS URBAN PHARMACEUTICALS INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:UCB, INC.;REEL/FRAME:037140/0203 Effective date: 20151125 |
|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., NEW YORK Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:KREMERS URBAN PHARMACEUTICALS INC.;REEL/FRAME:037171/0914 Effective date: 20151125 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC.;REEL/FRAME:054566/0585 Effective date: 20201207 |
|
AS | Assignment |
Owner name: KREMERS URBAN PHARMACEUTICALS INC., NEW JERSEY Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:ALTER DOMUS (US) LLC (SUCCESSOR TO MORGAN STANLEY SENIOR FUNDING, INC.);REEL/FRAME:056031/0185 Effective date: 20210422 Owner name: CODY LABORATORIES, INC., PENNSYLVANIA Free format text: RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNOR:ALTER DOMUS (US) LLC (SUCCESSOR TO MORGAN STANLEY SENIOR FUNDING, INC.);REEL/FRAME:056031/0185 Effective date: 20210422 |